Macroinvertebrate Community Index

O.C. Tanner Unveils 2023 Global Culture Report as Workplaces and Organizations Continue to Evolve and Rebuild Connection in a Post-Pandemic World

Retrieved on: 
Wednesday, September 28, 2022

SALT LAKE CITY, Sept. 28, 2022 /PRNewswire/ -- O.C. Tanner, the global leader in employee recognition and workplace culture, today announced the release of its 2023 Global Culture Report. Now in its fifth year, the report details the latest trends and strategies to win and retain people, including: reconnecting workplace community, creating fulfilling employee experiences, fortifying weary leaders, and integrating recognition and symbolism early and often. Based on data gathered from over 36,000 employees, leaders, HR practitioners, and executives from 20 countries worldwide, the report was announced at O.C. Tanner's sold-out annual culture conference, Influence Greatness.

Key Points: 
  • Tanner , the global leader in employee recognition and workplace culture, today announced the release of its 2023 Global Culture Report.
  • We hope this report will act as a guide for organizations and enable leaders to support, challenge, and inspire their employees to do great work."
  • As organizations prepare for the next crisis, employees are still trying to heal from the disconnection caused by the pandemic.
  • Tanner Institute uses multiple research methods to support the Global Culture Report, including interviews, focus groups, cross-sectional surveys, and a longitudinal survey.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA21

Retrieved on: 
Tuesday, October 5, 2021

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • This presentation is the first report on the long-term safety and effectiveness follow-up outcomes of these independent prespecified cohorts.
  • The IN.PACT Global Study was a prospective, multicenter, single-arm study conducted at 64 international sites that enrolled 1,535 participants, including some with complex lesions.
  • Assessments through 5 years included freedom from clinically driven target lesion revascularization (CD-TLR), safety composite, and major adverse events.